May Webinar-Introducing Ovid & Graviton’s New ROCK2 Inhibitor for CCM

Picture of Jeremy Levine a white male with glasses smiling. A picture of Amy Melsaether, a white woman with brown hair smiling.


Join us Thursday, May 16th at 7 pm ET/4 pm PT

Learn about a ROCK2 Inhibitor medication being developed by Ovid Therapeutics and Graviton Bioscience with the potential to have a significant impact on the treatment of Cavernous Malformation. Join us for a conversation with Amy Melsaether, MD, Chief Medical Officer, Graviton BioScience, and Jeremy Levin, CEO, Ovid Therapeutics.

Register for the webinar here.